Study outcome won't sway company on eye drug

Courtesy Headlines from the Associated Press  Wed, 08/27/2008 - 12:18

WASHINGTON (AP) -- What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?...


 

More related items

FDA clears first implantable telescope for vision
WASHINGTON (AP) -- U.S. health officials have approved a first-of-its-kind technology to counter a leading cause of blindness in older adults - a tiny telescope implanted inside the eye....

New 'research' fee to hit your health insurance plan
Starting in 2012, the government will charge a new fee to your health insurance plan for research to find out which drugs, medical procedures, tests and treatments work best.

New child-adapted Chagas disease treatment approved...
(Drugs for Neglected Diseases Initiative) A new pediatric dosage form of benznidazole for the treatment of Chagas disease, a potentially fatal neglected tropical disease, has been approved...

The Unwritten Rules of Friendship: Simple Strategies...
"Nobody likes me!" is a complaint that parents hear all too often, and few utterances make them feel more helpless. Now help is at hand: This practical and compassionate guidebook enables...

Burt's Bees Free Head to Toe Starter Kit


 

Post new comment

The content of this field is kept private and will not be shown publicly.
health-fitness.marc8.com